SHANGHAI, Sept. 20, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, today released the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study on Transcatheter Cardiovascular Therapy conference (TCT 2022),one of the world’s most influential cardiovascular conference. PADN is an innovative radiofrequency ablation technique in treating PH, was recognized as […]
Coronary/Structural Heart
Neovasc Provides Corporate Update Following Clinical Data Release
New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease VANCOUVER and MINNEAPOLIS, Sept. 20, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference (“TCT”) held September 16-19 in Boston. Prof. Shmuel Banai, MD, Neovasc […]
Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT™ at TCT 2022
Statistically significant mean reductions of 10.3 mmHg in 24-hour ambulatory systolic blood pressure and 11.7 mmHg in ambulatory pulse pressure after 6 months of therapy in control patients who crossed over to BackBeat CNT following completion of the randomized portion of the MODERATO II study NEW HOPE, Pa., Sept. 20, […]
Otsuka Medical Devices Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting
Study of the Paradise™ Ultrasound Renal Denervation System Shows significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension TOKYO–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) a wholly owned subsidiary of Otsuka Holdings today announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating […]
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
BOSTON–(BUSINESS WIRE)–Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis. This study is an update to a 2020 interim analysis and was announced at the 2022 […]
Advanced NanoTherapies’ SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease
Breakthrough Designation Reinforces Significant Unmet Need in Treatment of Small Vessel Coronary Arteries LOS GATOS, Calif., Sept. 19, 2022 /PRNewswire/ — Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant challenges through the creative applications of nanotechnology, today announced the U.S. Food and Drug Administration (FDA) has […]
Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL™ Cerebral Protection System
Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ — Boston Scientific Corporation ( NYSE:BSX) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection System, which is designed to capture and remove embolic debris stemming from transcatheter aortic valve […]
Late-Breaking Data Show Breadth of Abbott’s Minimally Invasive Structural Heart Technologies
Five late-breaking presentations at TCT 2022 highlight the impact of Abbott’s structural heart devices to repair or replace heart valves and close openings in the heart New data reinforce the safety and effectiveness of MitraClip™ for treating mitral regurgitation Results also demonstrate the benefits of Abbott’s TriClip™ for tricuspid regurgitation, […]
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
BOSTON–(BUSINESS WIRE)–Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in patients who received left ventricular (LV) unloading with Impella CP for 30 minutes prior to their percutaneous coronary intervention (PCI) compared to patients who received LV unloading […]
TCT 2022: SYMPLICITY HTN-3 trial data show sustained long-term blood pressure reductions with Medtronic renal denervation procedure
Long-term analysis from landmark renal denervation trial presented as Late Breaking Clinical Science, published simultaneously in The Lancet Data add to growing body of evidence supporting the durability of the Symplicity blood pressure procedure DUBLIN and BOSTON, Sept. 18, 2022 /PRNewswire/ — Medtronic plc ( NYSE: MDT), a global leader in healthcare technology, today announced long-term results […]



